It was a pleasure to meet with Prof. Kevin Garey (University of Houston College of Pharmacy, Houston, TX, USA) to discuss the results from the ECOSPOR phase 3 trial, and how SER-109 impacts patients’ health-related quality of life. Watch Part 1 of this interview here.
The abstract entitled: ‘The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
Questions:
- What is SER-109 and how is it manufactured? (0:13)
- What have we learned from the ECOSPOR III study about the impact of SER-109 on recurrent C difficile infections? (0:45)
- What were the findings of the health-related quality of life analysis? (1:50)
- What questions remain unanswered and what future studies are planned? (3:26)
Disclosures: Kevin Garey has research grants paid to his university from Seres Therapeutics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
